Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David A. Hyman, MD, JD, on Inclusive Shared Savings

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




May
18
Today In Oncology
FDA Approves Atezolizumab for Adjuvant Treatment of MRD-Positive MIBC
Sigmoidoscopy Reduces CRC Incidence Rates in Men in Norwegian Screening Study
Early Ovarian Cancer Minimally Invasive Surgery, Intraoperative Capsule Rupture, and Survival
Local Salvage Therapy for Post-Radiotherapy Local Recurrence of Prostate Cancer
Study Finds DLBCL Subtype May Have Higher Mortality Risk in Female Patients
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo